• Publications
  • Influence
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
  • J. Bean, C. Brennan, W. Pao
  • Biology, Medicine
    Proceedings of the National Academy of Sciences
  • 1 November 2007
Analysis of tumor samples from multiple independent patient cohorts and array-based comparative genomic hybridization suggest that MET amplification occurs independently of EGFRT790M mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib.
Neuroendocrine Tumors of the Lung With Proposed Criteria for Large‐Cell Neuroendocrine Carcinoma: An Ultrastructural, Immunohistochemical, and Flow Cytometric Study of 35 Cases
Although the prognosis of LCNEC appears to be intermediate between AC and SCLC, larger numbers of patients will be needed to demonstrate significant differences in survival, and any advantage to IHC, EM, or flow cytometry over light microscopy in the subclassification or prediction of prognosis is not found.
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
A comprehensive integrated genomic study of 74 MPMs provided a deeper understanding of histology-independent determinants of aggressive behavior, defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM.
Germline BAP1 mutations predispose to malignant mesothelioma
A BAP1-related cancer syndrome is identified that is characterized by mesothelioma and uveal melanoma, and it is hypothesized that other cancers may also be involved and that mesot helioma predominates upon asbestos exposure.